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period 2001-2007. Methods: A logistic regression was performed aspatially and at 
the nodes of a 5 km spacing grid overlaid over Florida and using all the cancer cases 
within a radius of 125 km of each node. Each observation was weighted as a function 
of its proximity to the center of the window (bisquare adaptive weight function). 
Covariates included age, race, marital status, smoking, type of health insurance 
and diagnosis facilities, presence of comorbidities (healthy (no comorbidity), aver-
age (1-2 comorbidities), above-average), census-tract median income and presence 
of farmhouse, year of diagnosis, county-level provider-to-case ratios. Results: 
Variables increasing the likelihood of late-stage diagnosis included having 1 to 2 
comorbidities (odds= 1.697) and more than 2 comorbidities (odds= 3.963), smoking 
(odds= 1.283), being African American (odds= 1.199) and living in census tracts with 
farmhouses (odds= 1.124). Having private insurance (odds= 0.533), having public 
insurance (odds= 0.470), being married (odds= 0.787) or diagnosed in a for-profit 
facility (odds= 0.886), as well as living in census tracts with high income (odds= 0.994) 
reduces the likelihood. ConClusions: There are significant spatial associations 
between late-stage prostate cancer incidence and observed individual, socioeco-
nomic, behavioral, environmental and demographic factors in Florida. This empha-
sizes the need for local strategies and cancer control interventions to reduce the 
percentage of late-stage diagnosis and ultimately eliminate health disparities.
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objeCtives: Differences in cancer incidence and mortality are apparent among vari-
ous demographic groups. Understanding the underlying determinants that place cer-
tain population subgroups at higher incidence and/or mortality of prostate cancer is 
imperative. Analyzing temporal trends can provide a comprehensive picture of the 
burden of the disease and generate new insights about the impact of various interven-
tions. This study aims to use advanced geospatial and temporal statistical techniques 
to model temporal trends in prostate cancer incidence and mortality and their geo-
graphical variations across Florida. Methods: Annual census-tract level rates were 
computed over the period 1981-2007 for two races (white and black), two categories of 
age (40-65, > 65) and five classes of incomes. They were then smoothed using binomial 
kriging to filter the noise caused by small population sizes. Joinpoint regression and new 
disparity statistics were applied to analyze temporal trends and detect potential racial 
and socio-economic differences. Results: Bivariate analysis of time-series indicated 
that late-stage diagnosis was generally more prevalent among blacks compared to 
whites, for age category 40-64 compared to older patients who are covered by Medicare, 
and among classes of lower socio-economic status. Joinpoint regression showed that 
the rate of decline in late-stage diagnosis for the two racial groups was similar among 
older patients (i.e. parallel time series). Both races displayed distinct spatial patterns 
with higher rates of late-stage diagnosis in the Florida Panhandle for white males 
whereas high rates clustered in South-eastern Florida for black males. ConClusions: 
The observed impact of socioeconomic and demographic factors on temporal trends 
in health outcomes emphasizes the need for local strategies and cancer control inter-
ventions to reduce late-stage diagnosis and improve health outcomes. Furthermore, 
large variations in the temporal trends in prostate cancer incidence and mortality and 
geographical variations would have important implications for resource allocation.
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objeCtives: Increased comorbid/mortality risk accompanies both excess weight 
and cancer. Charlson comorbidity index (CCI) scores in obesity and cancer 
were examined across two distinct populations and study designs. Methods: 
Comprehensive, electronic medical record (EMR) 2013 data from Clalit, a payer-
provider, closed-system health fund covering 55% of the Israeli population, were 
used to assess cancer diagnosis (vs. no cancer) and obesity (BMI≥ 30 vs. less) among 
individuals aged 21+ in Israel (n= 2,552,720). Similarly examined were 2013 adult 
(21+) respondents in the U.S. NHWS (n= 71,118), a cross-sectional, self-reported 
online survey. CCI, a weighted sum of comorbidities predicting mortality risk, was 
calculated based on registry diagnostic codes (Clalit) or self-reported diagnosis 
(NHWS). CCI categories and mean scores were compared across obesity/cancer 
groups and within age strata. Results: Proportions or patterns of individuals with 
CCI= 1+ were comparable across age brackets (21-49, 50-64, 65+) in Clalit (10.5%, 
43.3%, 66.7%, respectively) and NHWS (14.1%, 33.1%, 44.3%). CCI was higher among 
those with vs. without cancer (or obese vs. non-obese), all p< 0.05, among both 
Israeli (Clalit) and U.S. (NHWS) individuals. Across non-obesity/non-cancer, obesity/
non-cancer, non-obesity/cancer, and obesity/cancer groups, significantly increasing 
proportions of individuals had CCI= 1+ in both Clalit (23.4%, 41.9%, 68.7%, 77.2%, 
respectively) and NHWS (16.7%, 31.3%, 56.5%, 70.0%), plus increasing CCI means in 
Clalit (0.40, 0.80, 1.80, 2.10) and NHWS (0.25, 0.45, 1.38, 1.73), all p< 0.05. These pat-
terns replicated within the different age brackets. ConClusions: Across distinct 
data sources (Israeli insurance-clinical EMR and U.S. online survey), comparable 
comorbidity rates emerged within corresponding age brackets (notwithstanding 
“healthy cohort” effects observed among NHWS respondents aged 65+), and similar 
patterns of increased risk emerged with both cancer and obesity. This underscores 
the global challenge posed by the “dual-risk” profile of obesity with cancer history. 
Moreover, comprehensive and integrated EMR data can produce convergent results 
with validated, self-reported data, across diverse geographies.
age with mechanical stapling – which has potential to improve patient outcomes, 
lower re-operation rates and lower costs.
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objeCtives: Lung cancer is the first cause of cancer death in both men and women 
worldwide and 85% are NSCLC. As a targeted therapy for NSCLC, EGFR-TKIs has been 
compared with traditional chemotherapy in various trials in different countries 
but there is a lack of comprehensive literature review of these RCTs especially 
from Health-Related Quality of Life (HRQoL) perspective. We compared the effi-
cacy, safety and HRQoL between EGFR-TKIs(gefitinib, erlotinib and afatinib) and 
chemotherapy for advanced NSCLC patients with largest magnitude. Methods: 
Two authors independently searched published RCTs comparing EGFR-TKIs vs 
chemotherapy for advanced NSCLC between Jan 1, 1966 and July 31, 2013 in PubMed, 
Cochrane Library, EMBASE, the conference proceedings of ASCO and ESMO. We con-
ducted meta-analysis by Revman 5.0 using either random or fixed effects inverse 
variance weighted method, determined by heterogeneity levels. Results: Twenty-
two eligible studies and 6728 patients were included. Comparing to chemotherapy, 
EGFR-TKIs were superior in objective response rate (OR= 1.90, 95% CI= 1.32-2.57, 
P< 0.00001) and progression free survival (HR= 0.78, 95%CI= 0.66-0.91, P< 0.00001). 
However, no significant differences were observed on disease control rate (OR: 1.24; 
95% CI= 0.89-1.73), median overall survival (HR= 1.00; 95%CI= 0.93-1.07) and 1-yr 
survival rate (OR= 0.96; 95% CI = 0.82-1.13). EGFR-TKIs demonstrated less adverse 
events in neutropenia (OR= 0.01, 95% CI= 0.01-0.02), anemia (OR= 0.2, 95% CI= 0.14-
0.31), fatigue (OR= 0.18, 95% CI= 0.12-0.29) and nausea (OR= 0.35, 95% CI= 0.21-0.60) 
and less grade 3 or 4 adverse events (OR= 0.29, 95%CI= 0.26-0.33). However, chemo-
therapy had less rash (OR= 7.18, 95% CI= 4.67-11.05) and diarrhea (OR= 2.10, 95% 
CI= 1.49-2.98). In 8 studies evaluating the HRQoL, EGFR-TKIs had shown better out-
comes than chemotherapy according to the three HRQoL instruments: Functional 
Assessment of Cancer Therapy-Lung (OR= 1.62, 95% CI= 1.38-1.91), Trial Outcome 
Index (OR= 1.93, 95%CI= 1.61- 2.33), and Lung Cancer Subscale (OR= 1.19, 95%CI= 1.01-
1.39). ConClusions: Though no obvious survival benefit was observed, EGFR-TKIs 
demonstrated significantly better safety and HRQoL outcomes than chemotherapy.
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objeCtives: To determine the comorbidity burden and the association of specific 
pre-existing chronic-conditions with colorectal cancer (CRC) stage-at-diagnosis, 
treatment, and survival among elderly Medicare beneficiaries from a rural popula-
tion. Methods: This population-based retrospective cohort study used data on 
fee-for-service Medicare beneficiaries diagnosed with CRC and chronic-conditions 
between 2003-2006, identified from the West Virginia Cancer Registry (WVCR)-
Medicare linked database (n= 2,119). Beneficiaries were classified in specific chronic-
condition clusters. CRC-treatment received was ascertained from beneficiaries’ 
Medicare claims by following them for 12-months from their CRC-diagnosis date 
or until death. Receipt of minimally-appropriate CRC treatment (MACT) as defined 
by National Cancer Institute CRC-treatment guidelines and receipt of CRC-related 
surgery, chemotherapy, and radiation were examined. All-cause and CRC-specific 
mortality in the 36-month period following the CRC-diagnosis were examined, 
after accounting for selection bias using inverse probability treatment weights and 
adjusting for socio-demographics, cancer site and stage-at-diagnosis, receipt of 
MACT, and pre-existing conditions. Results: The WVCR-Medicare linked data-
base had a higher proportion of beneficiaries as compared to those from national 
data across almost all the condition clusters including previous-malignancy, COPD, 
depression, gastrointestinal conditions, heart-conditions, hypertension, liver-
conditions, and renal-conditions. Beneficiaries from the WVCR-Medicare linked 
database with most chronic-conditions were generally not likely to be diagnosed at 
distant-stage CRC, and possibly not as less aggressively treated for CRC as reported 
by some other studies. Only a few conditions were negatively associated with CRC-
specific mortality including depression (adjusted hazards ratio (AHR)= 1.25;95%CI
= [1.08,1.46]), and liver-conditions (AHR= 1.38;95%CI= [1.19,1.60]). However, almost 
all chronic-conditions were negatively associated with all-cause mortality in this 
study. ConClusions: This study highlights the need to focus on cancer-care that 
is better integrated with co-management of chronic-conditions, especially among 
those from rural-areas who are likely to have a high comorbidity burden.
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objeCtives: To account for the non-stationarity of relationships in space, aspatial 
regression can be supplemented with geographically-weighted regression (GWR), 
whereby the regression model is fitted within local windows and each observation 
is weighted according to its proximity to the center of the window. This study aims 
to conduct regression analysis in a spatial context to assess the local impacts of 
putative factors on late-stage diagnosis of prostate cancer in Florida during the 
